Drug: Lipitor
Company: Pfizer
Total spend Q1, 2012: $44.5 million
Total spend Q1, 2011: $71.9 million
Watch the TV commercial here >>

Lipitor lost patent protection in November, and while the company made some efforts to hold onto market share, it is clear from the reduced ad spend numbers that Lipitor has also lost its luster for Pfizer ($PFE). The company has been quietly winding down its marketing of the cholesterol fighter as generics makers have stripped it of sales. In the first quarter, Lipitor not only lost its hold on first place as the top selling drug--that honor went to Bristol-Myers Squibb's ($BMY) Plavix--it fell all the way to 14th place with $841 million in sales, surpassed even by its own generic copycats, which brought in $950 million.


Suggested Articles

Industry watchers have been speculating about just how high Novartis would price gene therapy Zolgensma. And now, they have an answer.

The WHO’s role in part is to provide prescribing guidance without an eye on profits. What happens when that guidance is tainted by private money?

After 19 sales reps left Amgen to help Karyopharm launch a rival multiple myeloma drug, Amgen sued. Now Karyopharm wants the suit thrown out.